A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer.

Front Oncol · 2026 · PMC13056818 · PMID 41959926

Europe PMC DOI

hedged sentences

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

did not reach statistical significancep=0.071so close (0.05 < p ≤ 0.1)

Analysis using a random-effects model showed that the V3 variant was associated with worse OS, but this did not reach statistical significance (HR = 1.99, 95%CI: 0.94-4.22, p=0.071) ( Figure 4A ).

also in 111,027 other papers

showed a trendno p-value reported

In patients receiving treatment across all lines (mixed first-line and later-line therapy), V3 showed a trend toward worse PFS compared with V1, but this did not reach statistical significance (HR = 1.26, 95%CI:0.87-1.83, p=0.277) ( Figure 7 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.